Teniposide

Teniposide (VM-26) is a semisynthetic derivative of podophyllotoxin and are increasingly used in Y medicine; causing breaks in DNA via an interaction with DNA topoisomerase II. (In Vitro) :Teniposide is a topoisomerase II inhibitor. Teniposide (VM-26, 0.15-45 mg/L) inhibits the proliferation of Tca8113 cells in a dose-dependent manner, with an IC50 of 0.35 mg/L. Teniposide (5 mg/L) induces apoptosis of Tca8113 cells. Teniposide (5.0 mg/L) causes cell arrested at G2/M phase in Tca8113 cells. Teniposide is active on primary cultured glioma cells from patients, when the level of miR-181b is high in the cells, with an IC50 of 1.3 ± 0.34 μg/mL. Cells treated with teniposide with low MDM2 have decreased viability compared with control cells, and the IC50 decreases from 5.86 ± 0.36 μg/mL to 2.90 ± 0.35 μg/mL upon MDM2 suppression. Teniposide also inhibits the viability of glioma cell with high level of miR-181b, through mediation of MDM2. (In Vivo) :Teniposide (0.5 mg/kg, i.p.) significantly increases micronucleated polychromatic erythrocyte (MNPCE) frequencies, which is directly related to bone marrow toxicity as significant suppression of bone marrow is noted. Teniposide (24 mg/kg, i.p.) markedly decreases the frequencies of BrdU-labelled sperm. Teniposide (12, 24 mg/kg, i.p.) also dramatically induces disomic sperm in the germ cell of male mice.

29767-20-2

NSC 122819 | VM-26

Pharmacology & Drug Discovery

>98% (HPLC)

DMSO: 40 mg/mL (60.91 mM)

O=C1OC[C@]2 ([H]) [C@H] (O[C@H]3[C@H] (O) [C@@H] (O) [C@]4 ([H]) O[C@H] (C5=CC=CS5) OC[C@@]4 ([H]) O3) C6=C (C=C7OCOC7=C6) [C@H] (C8=CC (OC) =C (O) C (OC) =C8) [C@]21[H]

C32H32O13S

656.66

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.